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ABSTRACT HLA-C expression is associated with a differential ability to control HIV-1
infection. Higher HLA-C levels may lead to better control of HIV-1 infection through
both a higher efﬁciency of antigen presentation to cytotoxic T lymphocytes and the
triggering of activating killer immunoglobulin-like receptors on NK cells, whereas
lower levels may provide poor HIV-1 control and rapid progression to AIDS. We
characterized the relative amounts of HLA-C heterotrimers (heavy chain/2 micro-
globulin [2m]/peptide) and HLA-C free heavy chains on peripheral blood mononu-
clear cells (PBMCs) from healthy blood donors harboring both alleles with stable or
unstable binding to 2m/peptide. We analyzed the stability of HLA-C heterotrimers
of different allotypes and the infectivity of HIV-1 virions produced by PBMCs with
various allotypes. We observed signiﬁcant differences in HLA-C heterotrimer stability
and in expression levels. We found that R5 HIV-1 virions produced by PBMCs harbor-
ing unstable HLA-C alleles were more infectious than those produced by PBMCs car-
rying the stable variants. We propose that HIV-1 infectivity might depend both on
the amounts of HLA-C molecules and on their stability as trimeric complex. Accord-
ing to this model, individuals with low-expression HLA-C alleles and unstable bind-
ing to 2m/peptide might have worse control of HIV-1 infection and an intrinsically
higher capacity to support viral replication.
IMPORTANCE Following HIV-1 infection, some people advance rapidly to AIDS while
others have slow disease progression. HLA-C, a molecule involved in immunity, is a
key determinant of HIV-1 control. Here we reveal how HLA-C variants contribute to
the modulation of viral infectivity. HLA-C is present on the cell surface in two differ-
ent conformations. The immunologically active conformation is part of a complex
that includes 2 microglobulin/peptide; the other conformation is not bound to 2
microglobulin/peptide and can associate with HIV-1, increasing its infectivity. Individ-
uals with HLA-C variants with a predominance of immunologically active conforma-
tions would display stronger immunity to HIV-1, reduced viral infectivity and effec-
tive control of HIV-1 infection, while subjects with HLA-C variants that easily
dissociate from 2 microglobulin/peptide would have a reduced immunological re-
sponse to HIV-1 and produce more infectious virions. This study provides new infor-
mation that could be useful in the design of novel vaccine strategies and therapeu-
tic approaches to HIV-1.
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Several host determinants inﬂuence HIV-1 replication and immune responsiveness,resulting in variable disease progression. Genetic variants of the major histocom-
patibility complex class I (MHC-I) genes represent critical determinants associated with
HIV-1 disease progression (1).
The MHC-I complex consists in a 45-kDa heavy  chain noncovalently associated
with a light  chain called 2 microglobulin (2m) and a short (8- to 11-mer) antigenic
peptide. In humans, the main  chains are encoded by the HLA-A, -B, and -C loci. The
role of MHC-I is to present foreign peptides to CD8 T cells, which recognize the
infected cells, and to control natural killer (NK) cell responses via interaction with killer
immunoglobulin-like receptors (KIRs) leading to inhibition or activation of their cyto-
lytic function (2).
HLA-C expression on the cell membrane is lower than that of HLA-A and -B (3, 4).
Several mechanisms are involved in the regulation of HLA-C cell surface expression. (i)
HLA-C itself does not efﬁciently associate with 2m (3) but, more importantly, shows
more selective peptide binding characterized by a lower afﬁnity constant than that of
HLA-A and -B (5). (ii) HLA-C has a dihydrophobic motif (L336-I337) in the cytoplasmic
tail that causes more rapid internalization than HLA-A and -B (6, 7). (iii) A subset of
HLA-C allotypes presents in the 3= untranslated region (UTR) of its mRNA a target
sequence for a microRNA (miR-148a) able to interfere at the posttranscriptional level
with HLA-C gene expression (8). Vince et al. recently reported a new single nucleotide
polymorphism (SNP), rs2395471, located in the HLA-C promoter region, associated with
variable HLA-C expression (9).
In addition to CD4, MHC-I molecules are also downregulated during HIV-1 infection.
Speciﬁcally, HIV-1 Nef is responsible for the internalization of HLA-A and -B (10–12),
while a recent study reported that Vpu downregulates HLA-C in primary HIV-1 isolates
(13).
During the process of budding from the cell membrane, HLA-C molecules are
incorporated into nascent HIV-1 virions together with other cell proteins, resulting in a
higher number of MHC-I molecules than HIV-1 Env trimers (14, 15).
MHC-I-negative cell lines are nonpermissive for the replication of primary HIV-1
isolates, but HLA-C transfection in these cells rescues HIV-1 replication competence
(16). Moreover, fusion efﬁciency is reduced in HLA-C-negative cells (17) and viruses
produced in HLA-C-silenced cells are signiﬁcantly less infectious than those produced
in HLA-C-expressing cells (18). Further studies demonstrated that HLA-C is selectively
incorporated into HIV-1 virions, associates with HIV-1 Env, and modulates viral infec-
tivity (19). We recently reported that the interaction between HIV-1 Env and HLA-C
selectively involves HLA-C free heavy chains present at the cell surface (20).
A genome-wide association study identiﬁed a SNP located 35 kb upstream of the
HLA-C coding region (rs9264942), associated with differences in HLA-C expression
levels, as a major genetic determinant of HIV-1 host control (1).
Subsequently, the causal variant responsible for these associations was identiﬁed in
a SNP (rs67384697) that maps in the 3= UTR mRNA of HLA-C alleles affecting the
binding of the microRNA Hsa-miR-148a (8). This SNP was shown to partially inﬂuence
cell surface expression of HLA-C with poorly expressing alleles that maintain an intact
miR-148a binding site (263G) and highly expressing alleles in which the site is deleted
(263del), thus escaping the regulation by interference exerted by that microRNA (8).
Increased HLA-C expression was associated with delayed progression to AIDS in both
African and European Americans, regardless of their distinct HLA-C frequencies and
linkage relationships with HLA-B and -A (21).
Adding complexity to this matter, other studies failed to conﬁrm the association
between HLA-C expression and these genetic markers (22–25). Furthermore, a study of
a very speciﬁc population in Nairobi, Kenya (26), found that the same HLA-C allotype,
HLA-C*07, could be associated with either a low (HLA-C*07:01) or an increased (HLA-
C*07:02) rate of seroconversion.
It has been hypothesized that higher HLA-C expression levels might trigger HIV-1-
speciﬁc responses by increasing antigen presentation to cytotoxic T lymphocytes (CTLs)
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(21), binding to KIRs on NK cells, or a combination of these mechanisms, explaining the
slower progression to AIDS (27).
The protective role of highly expressed HLA-C alleles in HIV-1 infection is in apparent
contrast to our previous studies suggesting a role for the HLA-C–Env association in the
enhancement of viral infectivity. We postulate here that this apparent contradiction
may stem from the presence of different HLA-C conformations (20, 28).
According to this hypothesis, differences among HLA-C allotypes in the modulation
of HIV-1 infectivity could rely on intrinsic differences in their binding stability as
heterotrimeric complexes. As a consequence, some HLA-C alleles might display a higher
dissociation rate than others, increasing the relative proportion of HLA-C free heavy
chains on the cell surface available for interaction with HIV-1 Env.
By using pulse-chase experiments, Sibilio et al. (28) studied the stability of HLA-C
assembly of eight serologically deﬁned alleles, showing that HLA-C*06, -*05, -*08, and
-*02 displayed greater stability than HLA-C*01, -*03, -*04, and -*07. Thus, to test our
working hypothesis, we deﬁned the ﬁrst as stable and the latter as unstable HLA-C
variants. In addition, since by neighbor-joining relationship analysis, HLA-C*12 and -*16
cluster with HLA-C*06, whereas HLA-C*15 clusters with HLA-C*02 and HLA-C*14 clusters
with HLA-C*01 (29), we classiﬁed HLA-C*12, -*15, and -*16 as stable variants and
HLA-C*14 as an unstable HLA-C variant.
Recently, Kaur et al. (30) reported that variations in the HLA-C 1/2 domains
inﬂuence the structure of the peptide-binding cleft and drive differential expression of
HLA-C allomorphs at the cell surface. They observed that HLA-C*05 binds a larger range
of peptides than HLA-C*07, thus stabilizing the trimeric complex on the cell surface.
These results further support our hypothesis and the rationale for our classiﬁcation,
since HLA-C*05 and -*07 are, respectively, classiﬁed as stable and unstable in the
present work.
We reported that HIV-1 infection increases HLA-C free chains on the cell surface (20).
HLA-C alleles with unstable binding to 2m/peptide might generate free chains able to
interact with HIV-1 Env, thus increasing viral infectivity.
The primary objective of the present study was to explore whether HLA-C alleles are
not only differently expressed but also show different stabilities as trimeric complexes.
To this aim, we compared the reactivities of two monoclonal antibodies (MAbs), DT9
and L31, speciﬁc for HLA-C/2m/peptide heterotrimers and HLA-C free chains, respec-
tively. The secondary objective was to preliminarily test in vitro whether HIV-1 infec-
tivity might be inﬂuenced by HLA-C stability by using prototype R5- and X4-tropic
viruses.
RESULTS
Study population. PBMCs were collected from 500 healthy bone marrow donors
enrolled at the Italian Bone Marrow Donor Registry (IBMDR) and followed by the Service
of Transfusion Medicine (AOUI, Verona, Italy). They were typed for HLA-A, -B, and -C by
high-resolution molecular biology methods.
Since different HLA-C allotypes may differ in the stability of 2m/peptide binding
and may be expressed at different levels, subjects with one stable and one unstable
HLA-C allele were excluded because they are expected to show intermediate pheno-
types. To highlight differences between the two allotype groups, we selected donors
harboring both HLA-C alleles belonging to either the stable or the unstable group.
In addition to HLA-C, DT9 and L31 recognize some HLA-B alleles (28, 29, 31, 32).
Thus, subjects expressing DT9 (HLA-B*13:01, -*35:01, -*40:06, and -*73:01)- and L31
(HLA-B*07, -*08, -*22, -*35, -*46, -*51, -*54, and -*56)-cross-reactive HLA-B allotypes were
also excluded. According to these criteria, only about 10% of the potential donors were
suitable for this study (Table 1).
The groups considered were homogeneous and did not show any difference in
gender (25/33 males in the stable group, 15/20 males in the unstable group; 2 test, P
0.9505) or age (mean age, 32.76 1.69 years in the stable group and 33.90 2.41 years
in the unstable group; t test, P  0.6919).
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We compared the frequency of HLA-C alleles in the donors selected for this study
with both the frequency of HLA-C alleles in the registered IBMDR donors and the frequency
of HLA-C alleles reported in northern Italy (33). We observed some differences (Fisher exact
test) between the selected population and the whole IBMDR population, in particular, an
increase in HLA-C*06 (P 0.0356), -*08 (P 0.0299), and -*12 (P 0.0412) frequencies and
a decrease in HLA-C*04 (P  0.0063) and -*15 (P  0.0291) frequencies in the selected
TABLE 1 Summary of the population studied




1 M 19 *02:01, *30:01 *40:01, *58:01 *03:02, *03:04 U
2 M 37 *11, *68 *37, *44 *06, *16 S
3 M 31 *02, *29 *18, *58 *07, *07 U
4 M 35 *02, *33 *14, *44 *05, *08 S
5 M 29 *02, *24 *44, *58 *07, *07 U
6 F 20 *02:01, *03:01 *27:05, *44:02 *02:02, *05:01 S
7 M 36 *02, *26 *15, *55 *03, *03 U
8 M 18 *11:01, *29:02 *39:01, *44:03 *12:03, *16:01 S
9 F 21 *25:01, *68:02 *39:01, *45:01 *12:03, *16:01 S
10 F 26 *02, *02 *15, *15 *04, *04 U
11 M 41 *24:02, *25:01 *18:01, *44:03 *12:03, *16:01 S
12 M 24 *02, *02 *44, *49 *05, *15 S
13 M 27 *02:01, *24:02 *38:01, *44:02 *05:01, *12:03 S
14 M 25 *02:01, *11:01 *38:01, *44:03 *12:03, *16:01 S
15 M 47 *02:01, *02:01 *44:05, *44:05 *02:02, *02:02 S
16 M 27 *02:01, *26:01 *15:01, *49:01 *04:01, *07:01 U
17 M 25 *23, *32 *15, *44 *01, *04 U
18 M 25 *02:01, *03:01 *15:01, *18:01 *03:03, *07:01 U
19 F 33 *26, *03 *13, *44 *05, *06 S
20 M 29 *11:01, *30:04 *44:02, *50:01 *06:02, *16:04 S
21 F 22 *02, *33 *14, *39 *08, *12 S
22 M 42 *03, *24 *39, *44 *04, *04 U
23 M 38 *02:01, *26:01 *18:01, *38:01 *12:03, *12:03 S
24 F 23 *11, *23 *18, *44 *04, *07 U
25 M 38 *26, *26 *37, *37 *06, *06 S
26 M 31 *01:01, *26:01 *38:01, *57:01 *06:02, *12:03 S
27 F 30 *02:01, *03:01 *13:02, *50:01 *06:02, *06:02 S
28 M 42 *02:01, *30:02 *18:01, *49:01 *05:01, *06:02 S
29 M 47 *31:01, *03 *18:01, *40:01 *03:04, *07:01 U
30 M 30 *30:02, *68:01 *18:01, *44:02 *02:02, *05:01 S
31 M 19 *01:01, *32:01 *14:01, *57:01 *06:02, *08:02 S
32 M 27 *02:01, *26:01 *18:01, *58:01 *07:01, *07:01 U
33 M 32 *33:01, *34:02 *14:02, *14:02 *08:02, *08:02 S
34 M 26 *03:01, *29:02 *39:06, *58:01 *07:01, *07:02 U
35 F 24 *01:01, *01:01 *37:01, *57:01 *06:02, *06:02 S
36 M 27 *01:01, *32:01 *41:02, *49:01 *07:01, *07:03 U
37 F 33 *01:01, *24:03 *18:01, *18:01 *07:01, *07:01 U
38 M 22 *02:01, *03:01 *38:01, *44:02 *05:01, *12:03 S
39 M 32 *01:01, *26:01 *37:01, *38:01 *06:02, *12:03 S
40 M 43 *11:01, *25:01 *18:01, *52:01 *12:02, *12:03 S
41 F 27 *25:01, *33:01 *14:02, *44:02 *05:01, *08:02 S
42 F 27 *03:01, *25:01 *13:02, *18:01 *06:02, *12:03 S
43 M 35 *02:01, *02:01 *18:01, *44:02 *07:01, *07:04 U
44 M 33 *03:01, *11:01 *14:01, *18:01 *05:01, *08:02 S
45 F 53 *24:02, *32:01 *37, *44 *01:02, *04:10 U
46 F 54 *11:01, *23:01 *44:02, *38:02 *04:01, *07:02 U
47 M 53 NAc *49, *58 *07, *07 U
48 M 40 NA *15, *49 *07, *07 U
49 M 50 *02:01, *29:01 *18, *44 *08:09, *16:01 S
50 M 39 *24:02, *30:11 *13:02, *37:01 *06, *06 S
51 M 43 NA *37, *44 *06, *16 S
52 M 57 NA *38, *52 *12, *12 S
53 M 45 *01:01, *02:05 *15:03, *49:01 *06, *12 S
aM, male; F, female.
bS, stable; U, unstable.
cNA, not available.
Parolini et al. Journal of Virology














population. These differences are most likely due to the exclusion from the study of
donors with cross-reactive HLA-B alleles which are in linkage disequilibrium with
speciﬁc HLA-C alleles, since haplotypes tend to be inherited together as a haplotype
block. Some common haplotypes in the Italian population are indeed reported to be
HLA-B*35:01–HLA-C*04:01 and HLA-B*51:01–HLA-C*15:02 (Allele Frequency Net Data-
base [AFND]; http://www.allelefrequencies.net) (34).
Exclusion of cross-reactive HLA-B alleles is necessary; this might have been a serious
ﬂaw in previous studies. In addition, MAb DT9 has been reported to be cross-reactive
with HLA-E (35, 36). Lo Monaco et al. reported some concerns about this cross-
reactivity, which may lead to overestimation of the presence of HLA-C on the cell
surface (37). A later study (38), although conducted with a speciﬁc HLA-A, -B, and -C
haplotype, reported that HLA-E is expressed at an about 25 times lower level that
HLA-C, thus reducing concerns about the signiﬁcance of MAb DT9 HLA-E cross-
reactivity.
Flow cytometry analysis of different HLA-C conformations on the cell surface.
Preliminary control experiments showed no relevant differences in HLA-C stability
between PBMCs and lymphocytes measured by analyzing L31 and DT9 reactivity. A
representative comparison of PBMCs and lymphocytes of donors harboring unstable
and stable HLA-C variants is reported in Fig. 1A and B, respectively. Thus, the following
analyses were performed with PBMCs, as these were used for Western blotting and
infectivity experiments.
Labeling with MAb L31 showed comparable levels of HLA-C free chains in the stable
and unstable groups (Fig. 2A; Wilcoxon test, P  0.9415).
FIG 1 Flow cytometry analyses of HLA-C/2m/peptide heterotrimers and HLA-C free chains. Gating strategies and representative histograms for the ﬂow
cytometry experiments are shown. MAb DT9 recognizes heterotrimers; MAb L31 recognizes HLA-C free chains. An acid wash was performed to remove
2m/peptide from HLA-C heterotrimers. Results for a subject with both unstable HLA-C alleles (A) and a subject with both stable HLA-C alleles (B) are shown.
Fold change was calculated as the ratio of RMFIs after and prior to the acid wash for MAb L31 and as the ratio of RMFIs prior to and after the acid wash for
MAb DT9. RMFIs were calculated as reported in Materials and Methods. MFIcontrol (secondary antibody control) was 0.19 or 0.26 for unstable PBMCs, 0.15 or 0.20
for unstable lymphocytes, 0.17 or 0.15 for stable PBMCs, and 0.12 or 0.10 for stable lymphocytes, respectively, without or with previous acid wash treatment.
Fold change analyses of PBMCs and lymphocytes from the same donor show similar results for both antibodies. FSC, forward scatter; SSC, side scatter.
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Similarly, the DT9 MAb (which recognizes the HLA-C/2m/peptide complex) did not
reveal signiﬁcant differences between the two groups (Fig. 2D; Wilcoxon test, P 
0.6712).
A marginal difference was observed when the L31 analysis was performed after acid
treatment (acid wash), which disrupts the majority of trimeric HLA-C complexes,
allowing the quantiﬁcation of a larger fraction of HLA-C free chains present on the cell
surface (Fig. 2B; Wilcoxon test, P  0.0563). As expected, the relative median ﬂuores-
cence intensity (RMFI) of L31 staining after the acid wash was higher than the RMFI of
constitutive L31, as visible by the different scale (Fig. 2A and B). Vice versa, as expected,
the RMFI of DT9 staining after the acid wash was lower than the RMFI of constitutive
DT9 (Fig. 2D and E). However, DT9 staining after the acid wash was signiﬁcantly higher
in the stable group (Fig. 2E; Wilcoxon test, P  0.0147), underlining the presence of a
larger pool of stable HLA-C trimers on these cells.
HLA-C/2m/peptide binding stability analysis. HLA-C/2m/peptide binding sta-
bility was measured as the fold change in ﬂuorescence calculated as the ratio of L31
MAb reactivities after and before acid wash treatment. This value represents the
proportion of HLA-C free heavy chains released after the disruption of the trimeric
FIG 2 MAb L31 and DT9 ﬂow cytometry analyses of HLA-C conformations expressed on the plasma membrane of PBMCs. Results obtained with cells from
selected donors harboring unstable (black dots) or stable (white dots) HLA-C variants are displayed. Horizontal bars indicate medians and quartiles. Comparisons
(Wilcoxon test) of the two groups: A, MAb L31, speciﬁc for HLA-C free chains, unstable n  20, stable n  33; B, MAb L31, after an acid wash to remove 2m,
unstable n  20, stable n  33; C, L31 RMFI fold change in ﬂuorescence, expressed as the ratio of the L31 RMFI after an acid wash to the L31 RMFI prior to
the acid wash, unstable n  20, stable n  33; D, MAb DT9, speciﬁc for properly folded HLA-C heterotrimers, unstable n  18, stable n  32; E, MAb DT9, after
an acid wash to remove 2m, unstable n  13, stable n  27; F, L31 RMFI fold change in ﬂuorescence, expressed as the ratio of the DT9 RMFI prior to an acid
wash to the DT9 RMFI after an acid wash, unstable n  13, stable n  27.
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complexes and those constitutively present on the cell surface as a consequence of the
natural instability of the HLA-C/2m/peptide complexes. If the proportion of HLA-C in
its free heavy chain conformation is greater than that of HLA-C heterotrimers, this ratio
will be marginally inﬂuenced by the acid wash treatment and the L31 fold change in
ﬂuorescence will be relatively low. Vice versa, if HLA-C molecules are present mainly as
heterotrimers, the acid wash treatment will have a greater effect in switching the HLA-C
conformation and consequently the L31 fold change ratio will be higher.
Our hypothesis was that HLA-C allotypes classiﬁed as stable are more stably asso-
ciated with 2m/peptide and consequently present a smaller proportion of free heavy
chains than unstable allotypes. Therefore, larger and smaller fold increases in ﬂuores-
cence should be expected for the stable and unstable allotypes, respectively.
Indeed, ﬂow cytometric analyses indicated that cells from subjects in the unstable
group have a signiﬁcantly smaller fold change in ﬂuorescence than those from subjects
in the stable group (Fig. 2C; Wilcoxon test, P  0.0063). We did not observe the
prevalence of certain HLA-C allotypes in those subjects showing the greatest fold
change in ﬂuorescence, excluding the involvement of speciﬁc HLA-C variants. On the
contrary, no difference was observed when the DT9 RMFI fold change was analyzed
(Fig. 2F; Wilcoxon test, P  0.1794).
The difference in the L31 RMFI fold change observed in PBMCs was further con-
ﬁrmed in a cell line model. We used 721.221-CD4 cells, which harbor a deletion of the
MHC-I locus, transfected with either the HLA-C*06 (stable) or the HLA-C*07 (unstable)
gene. Flow cytometry analysis with MAb L31, with or without an acid wash, revealed a
greater fold change in ﬂuorescence in HLA-C*06-expressing cells than in HLA-C*07-
expressing cells in four independently replicated experiments (Fig. 3; two-way analysis of
variance [ANOVA], P  0.0297). This result conﬁrmed the data obtained with PBMCs
indicating that HLA-C*06 has a greater stability of the trimeric complexes than HLA-C*07.
This experiment, performed in a controlled cellular model, excluded any other variable due
to individual differences between subjects or to immune system involvement.
Different total HLA-C expression levels in stable and unstable groups. To test
total HLA-C expression levels in our study population, we performed Western blot
analyses of whole PBMC lysates. In addition, we assessed 2m expression levels.
Signiﬁcantly greater expression of HLA-C was observed in the stable group than in the
unstable group (Fig. 4A; Wilcoxon test, P  0.0312), whereas no signiﬁcant differences
in 2m expression levels were observed (Fig. 4B; Wilcoxon test, P  0.2109). The
FIG 3 Analysis of fold changes in ﬂuorescence in 721.221-CD4 cells. L31 RMFI fold changes in ﬂuores-
cence in HLA-C*07 (unstable, black dots)- and -*06 (stable, white dots)-expressing 721.221-CD4 cells are
shown. The graph represents the ﬂow cytometry results of four independent transfections; the dotted
lines connect results of the same transfection experiments. Two-way ANOVA was applied (fold change
as the dependent variable, HLA-C allele and experiment replicas as independent variables).
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signiﬁcantly higher total HLA-C expression in the stable group might be a consequence
of the higher expression of some HLA-C variants (i.e., HLA-C*02, -*06, and -*15)
associated with SNPs rs67384697 (8) and rs2395471 (9) grouped as stable and the lower
expression of variants (i.e., HLA-C*03 and -*07) grouped as unstable.
HLA-C allotypes modulate the infectivity of HIV-1 virions. The efﬁciency of
infection of primary mixed cells such as PBMCs is quite variable because of several different
factors (the numbers of CD4 and CD8 T lymphocytes, expression of HIV-1 coreceptors,
phytohemagglutinin [PHA] activation, cell growth, cell viability); thus, we set up a stan-
dardized system to compare the inﬂuences of stable and unstable HLA-C alleles on
infectivity. To this aim, PBMCs from a donor with stable HLA-C allotypes and a donor with
unstable HLA-C allotypes were randomly coupled and evaluated in parallel in the same
experimental set. PBMCs were infected with HIV-1, and supernatants were normalized for
p24 content and used to infect TZM-bl cells (39), thus minimizing the variability of the
target of infection. The TZM-bl cell line is stably transfected with a beta-galactosidase
(-Gal) and a luciferase plasmid under the control of the HIV-1 Tat promoter. Supernatants
from HIV-1 BaL (R5 tropic, Fig. 5A)- and IIIB (X4 tropic, Fig. 5B)-infected PBMCs from 16
donors (8 with stable and 8 with unstable HLA-C alleles) were used to infect TZM-bl
cells. To assess virion infectivity, three or four replicated input p24 concentrations were
utilized. For each experimental set, the ﬁrst viral concentration not showing an evident
cytopathic effect on cell viability was used for data analysis. Data were analyzed by
two-way ANOVA, untangling the effect of the variability between experimental sets and
the effect of HLA-C stability on viral infectivity. Signiﬁcantly higher infectivity [p(HLA) 
0.0001] with the R5-tropic BaL HIV-1 isolate was observed in the unstable group than
FIG 4 HLA-C and 2m Western blot analyses of PBMCs. Densitometric analyses of Western blot (WB or wb) assays for HLA-C (A) and 2m (B) for unstable (black
dots) and stable (white dots) HLA-C allotypes are shown. Horizontal bars indicate medians and quartiles. For HLA-C (A), unstable n 16, stable n 28; Wilcoxon
test; for 2m (B), unstable n  14, stable n  27; Wilcoxon test. (C) Representative images of Western blot experiments used to quantify HLA-C (left) and 2m
(right) expression levels. Negative and positive controls are CHO and HEK-293T cell lysates for HLA-C and HEK-293T 2m-negative and HEK-293T cell lysates for
2m, respectively. The HLA-C allotype is depicted for the PBMC samples shown.
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in the stable one (Fig. 5A, left). No signiﬁcant difference was observed with the
X4-tropic HIV-1 IIIB isolate [Fig. 5B, left, p(HLA)  0.6785]. As expected, signiﬁcant
differences, due to the experimental set, were observed [p(EXP)  0.0001 and p(EXP) 
0.0003 for BaL and IIIB, respectively]. The two groups were also analyzed by comparing
the distributions of the mean infectivity of each subject. The Wilcoxon test showed a
signiﬁcant difference between the two groups in BaL infectivity (P  0.0357, Fig. 5A,
right) but not in IIIB infectivity (P  0.5995, Fig. 5B, right).
Finally, the infectivity of virions produced by 721.221-CD4 cells transfected with
either HLA-C*06 or -*07 was assessed. Since 721.221-CD4 cells endogenously express
CXCR4 but lack CCR5, they were infected with the HIV-1 IIIB isolate. The supernatants
collected on day 3 were quantiﬁed for p24 content and used to infect TZM-bl cells. As
shown in Fig. 6, the infectivity of virions produced by 721.221-CD4-C*07 cells was
signiﬁcantly greater than that of virions produced by 721.221-CD4-C*06 cells (two-way
ANOVA, P  0.0001).
DISCUSSION
Here we studied whether HLA-C variants differ in the stability of 2m/peptide
binding and whether the relative amounts of HLA-C/2m/peptide complexes and
FIG 5 Infectivity of HIV-1 virions produced by PBMCs. Histogram charts represent the mean HIV-1 infectivity and standard deviations of different randomly
coupled subjects harboring both stable (white bars) and unstable (black bars) HLA-C alleles. x axis, experimental set; y axis, virion infectivity expressed in RLU.
Statistically signiﬁcant differences were evaluated by two-way ANOVA. p(HLA) refers to virion infectivity due to the HLA-C group (stable/unstable), while p(EXP)
refers to experimental set variability. (A) Infection conducted with the R5-tropic BaL HIV-1 strain. (B) Infection conducted with the X4-tropic IIIB HIV-1 strain. Dot
charts represent the distributions of the mean infectivity of each subject (unstable HLA-C variants, black dots; stable variants, white dots). Horizontal bars
indicate medians and quartiles; data were analyzed by Wilcoxon test.
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HLA-C free heavy chains might be involved in the modulation of HIV-1 infectivity. Our
working hypothesis predicts that a greater proportion of free heavy chains should be
present on PBMCs obtained from individuals with unstable HLA-C alleles than on
PBMCs obtained from donors with stable HLA-C alleles.
We analyzed the relationship between HLA-C associated with 2m/peptide and
HLA-C free heavy chains (both as constitutive expression and after 2m/peptide
stripping) on PBMCs, since the simple detection of only trimeric complexes, as reported
previously (21, 24), might underestimate the actual amounts of HLA-C molecules that
reach the cell surface (20).
When PBMCs from donors expressing both stable and unstable HLA-C allotypes
were analyzed for HLA-C surface expression with either the DT9 (which recognizes
HLA-C heterotrimers) or the L31 (which recognizes HLA-C free heavy chains) MAb, no
signiﬁcant differences were detected, suggesting that the overall amounts of HLA-C
exposed at the cell membrane, although highly variable, are similar in the two groups.
The necessary exclusion of DT9 and L31 HLA-B cross-reactive alleles from the study
population, as well the different classiﬁcations of stable and unstable HLA-C alleles,
might explain why we did not observe differences previously reported by others (21).
Of note, an acid wash treatment prior to ﬂow cytometry dissociates the vast majority
of HLA-C trimers, resulting in a sharp increase and reduction in L31 and DT9 reactivity,
respectively. After the acid wash, higher, marginally signiﬁcant reactivity was observed
in the presence of stable alleles with MAb L31 and a higher degree of DT9-reactive
molecules was displayed by the stable group, indicating that although the overall
amount of HLA-C analyzed at the steady state on the cell surface was comparable in the
two groups, differences in the composition of the HLA-C pools do exist.
This crucial aspect was further addressed by calculating the L31 fold change in the
ﬂuorescence ratio as an indicator of HLA-C/2m/peptide binding stability. Hence, this
value was signiﬁcantly higher in the presence of stable HLA-C allotypes than in the
presence of unstable ones. Furthermore, the fold change in ﬂuorescence was analyzed
in a cellular model, 721.221-CD4 cells, where single speciﬁc HLA molecules can replace
the deletion of the MHC-I locus. 721.221-CD4 cells expressing HLA-C*06 (stable allele)
presented a greater L31 fold change than cells expressing HLA-C*07 (unstable allele).
The use of this cellular model, besides supporting our previous observations, excludes
FIG 6 Infectivity of virions produced by 221-CD4-C*06 (stable variant) and 221-CD4-C*07 (unstable
variant) cells. Four input p24 concentrations were used to infect TZM-bl cells in triplicate cultures. x axis,
p24 pg/well; y axis, virion infectivity expressed in OD units/min. Black dots and continuous line, virions
produced in 221-CD4-C*07 cells; white dots and dotted line, virions produced in 221-CD4-C*06 cells.
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any other genetic or immunological components that may interfere in the experiments
performed with PBMCs.
The signiﬁcant difference in the fold change in ﬂuorescence highlights a relevant
molecular property of these interacting proteins, i.e., the stability of the heterotrimeric
complexes that conﬁrms our working hypothesis and deﬁnes the HLA-C*02, -*05, -*06,
-*08, -*12, -*15, and -*16 allotypes as stable and the HLA-C*01, -*03, -*04, -*07, and
possibly -*14 allotypes as unstable. Although all of the HLA-C alleles tested for assembly
were characterized by a lower stability of the trimeric complexes than HLA-A or -B
alleles (28), some alleles belonging to the unstable group (HLA-C*03 and -*07) showed
the highest dissociation rate (28). Therefore, the presence of HLA-C on the cell mem-
brane appears to be mediated by a combination of different important phenomena, i.e.,
HLA-C expression levels, depending on both HLA-C mRNA regulation mediated by
miR-148a (21, 29) and, as more recently reported, by the SNP rs2395471 in the HLA-C
promoter region (9), and the peptide afﬁnity and stability of the HLA-C/2m/peptide
complexes, which, in combination, appear to determine not only the presence of
different amounts of HLA-C on the cell membrane but also a different proportion of
HLA-C full complexes and free heavy chains.
It is noteworthy that some low-expression HLA-C variants (9, 21), such as HLA-C*03
and -*07, are also the ones with lower 2m/peptide binding stability (28), while some
stable HLA-C variants, such as HLA-C*02, -*06, -*12, and -*16, are also highly transcribed
and expressed. This correlation is further highlighted by our observation, assessed by
Western blot assay, of signiﬁcantly lower HLA-C expression in the unstable group.
HLA-C*01 and -*04, highly expressed alleles according to Vince et al. (9), show lower
2m/peptide binding stability according to Sibilio et al. (28). Vince et al. did not report
HLA-C mRNA expression for these alleles, while other studies (22–25) did not report any
particular increase in their mRNA expression. Similarly, HLA-C*01 and -*04 were re-
ported to have a high surface reactivity to MAb DT9 (21), but since they are also less
stably bound to 2m/peptide, it is possible that DT9 staining underestimates the real
amounts of HLA-C molecules on the cell surface. In all cases, the expression of HLA-C
trimeric complexes on the cell surface depends on the integration of several factors
such as mRNA levels, posttranslational regulation, transport, and differential stability of
HLA-C alleles.
The proportion of HLA-C heterotrimers and free chains might play a role in the
modulation of HIV-1 infection. We have shown that HIV-1 speciﬁcally increases the
amount of free chains in cell lines either chronically or acutely infected (20). To study
whether HIV-1 infection affected the levels and distribution of heterotrimers/free chains
in PBMCs would have been a natural extension of our previous work, but here we chose
to explore an aspect we deemed more important at ﬁrst, which was whether the
infectivity of HIV-1 virions is affected by HLA-C stability.
Indeed, the infectivity of virions produced in PBMCs of donors harboring unstable
HLA-C alleles was signiﬁcantly higher than the infectivity of virions produced by PBMCs
of individuals carrying stable HLA-C alleles with the R5-tropic BaL HIV-1 isolate.
In addition, HIV-1 IIIB virions produced by 721.221-CD4-C*07 cells were more
infectious than those produced by 721.221-CD4-C*06 cells. This experiment, performed
in the same cellular background, conﬁrms our hypothesis on HIV-1 infectivity and
HLA-C stability. Vice versa, HIV-1 IIIB virions produced by PBMCs with unstable HLA-C
alleles were not signiﬁcantly more infectious than those produced by PBMCs with
stable alleles.
According to this ﬁnding, a virion budding from PBMCs carrying unstable alleles
might be more infectious because a greater proportion of HLA-C free chains would be
available to interact with HIV-1 Env (20), determining an infectivity increase, as well as
less susceptibility to neutralizing antibodies (16).
Fellay et al. (1) ﬁrst described the correlation between HLA-C alleles and viral load
variations during the asymptomatic set point period of infection, which is characterized
by the predominance of R5 variants (40). Our data ﬂow in the same direction, since the
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effect of unstable HLA-C alleles in enhancing viral infectivity is observed in PBMCs with
an R5-tropic virus.
In a previous paper (18), we reported that the infectivity of some CXCR4-tropic
isolates, namely, J500 and NDK, was not affected by the absence of HLA-C, suggesting
a reduced effect of HLA-C on X4-tropic isolates. The effect of unstable HLA-C variants
on the X4 HIV-1 isolate could be overshadowed by many other factors in the PBMC
model, while it is evident in the 721.221-CD4 controlled model, in which the only
difference is the expression of a stable (C*06) or unstable (C*07) variant.
The interplay between HLA-C and HIV-1 is a complex event, since HIV-1 requires the
expression of HLA-C on the cell membrane to be more infectious (17–19), but at the
same time, HLA-C participates in the activation of an appropriate CTL immune response
(21, 41). The ﬁnding that HLA-C allelic variants have a different impact on viral
infectivity in vitro, in the absence of any inﬂuence by the immune system, suggests that
the availability of HLA-C free heavy chains is important in the modulation of HIV-1
infectivity. These data unravel a novel relationship between HLA-C expression and
HIV-1, independent of cellular immunity.
Previous data published by our research groups (17–19) indicate that the presence
of HLA-C, particularly as free heavy chains, positively modulates the infectivity of HIV-1
as a result of the association with HIV-1 Env protein at the cell membrane level (20). This
effect may sum up and/or synergize with other determinants in deﬁning the set point
of individual HIV-1 infections.
The protective role of a higher expression level of HLA-C on the cell membrane
appears to be in contrast to the increased infectivity of HIV-1 when HLA-C is incorpo-
rated into the virion. The results of this study may explain this apparent contradiction.
Subjects with unstable HLA-C allotypes (HLA-C*01, -*03, -*04, -*07, and -*14) are
characterized by the presence of a larger pool of HLA-C free heavy chains on the cell
membrane, which in turn may increase viral infectivity. Conversely, subjects with stable
HLA-C allotypes (HLA-C*02, -*05, -*06, -*08, -*12, -*15, and -*16) are characterized by the
presence of a greater proportion of heterotrimers (HLA-C/2m/peptide) on the cell
membrane, which may stimulate cellular immunity and, consequently, determine
better control of HIV-1 infection.
The present study, performed with a small population, owes its strength to the
stringent selection carried out, which excluded all HLA-B allotypes cross-reactive with
the DT9 and L31 MAbs and included only donors carrying both HLA-C alleles belonging
to either the stable or the unstable group.
On the other hand, this same selection represents an extreme situation to test our
working hypothesis. Certainly, in the general population, a continuous range of levels
of susceptibility to HIV-1 infection would be expected because of the combination and
interaction of different HLA-C allele expression levels, different stability as surface
trimers, which follows a continuous rather than a bimodal pattern, and of many other
genetic variants that may contribute to the outcome of the disease. For instance, an
involvement of other HLA alleles could not be excluded. HLA-B*46, which is less stable
according to Sibilio et al. (28), has been associated with susceptibility to HIV-1 infection
(42). In the present study, we did not include subjects harboring HLA-B*46 because of
its cross-reactivity with MAb L31.
Our results suggest that the stability of HLA-C complexes, in addition to the levels
of HLA-C expression reported in previous studies, is involved in the modulation of HIV-1
infectivity. Their combination can inﬂuence the prediction of HIV-1 infection progres-
sion. In the asymptomatic, antiretroviral drug-untreated phase, individuals with low-
expression and unstable HLA-C alleles might have a more rapid disease progression,
whereas individuals with highly expressed and stable HLA-C alleles would better
control HIV-1 infection. Expression levels alone do not explain why HIV-1 requires
HLA-C on the cell membrane to be more infectious (16-18, 20) and, in addition, do not
explain the higher serum and cerebrospinal ﬂuid 2m concentrations observed in
HIV-1-progressing patients (43–46), which may accumulate because of HLA-C trimeric
complex instability.
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The restricted availability of sample material from PBMC donors limited this study to
testing of the infectivity of a reduced number of HIV-1 isolates. For the same reason, the
correlation between SNPs rs2395471 and rs67384697 and the stability of each HLA-C
allotype in PBMCs and puriﬁed CD4 HIV-1-infected T cells could not be studied. These
open questions deserve a new investigation.
HLA-C variants that may more easily dissociate will likely present a greater propor-
tion of free heavy chains, increasing HIV-1 infectivity and promoting 2m release, also
contributing to inﬂammatory states. It would be of interest to investigate whether
HIV-1 Env facilitates the spontaneous decay of HLA-C trimeric complexes originating
more HLA-C free chains available for Env interaction. Indeed, studies published in the
early years of the HIV-1 pandemic reported that patients with HIV-1 dementia pre-
sented a higher concentration of 2m in their cerebrospinal ﬂuid (45) and that 2m
levels were raised in the serum of AIDS-related complex patients (44) and during HIV-1
infection progression (43, 46). Our results start to shed some light on these never fully
explained observations; individuals with unstable HLA-C alleles might lose 2m, leading
to its accumulation in their serum and cerebrospinal ﬂuid. The role of 2m in neuro-
degenerative progression is not yet well deﬁned, but it is known that 2m molecules
can form ﬁbrils (47, 48) and may be neurotoxic (49, 50).
Our present work underlines the signiﬁcant role of HLA-C as a key player in the
control of HIV-1 infection (51).
MATERIALS AND METHODS
Population and HLA and SNP rs67384697 genotyping. The healthy blood donors involved in this
study were enrolled at the IBMDR, followed by the Service of Transfusion Medicine, AOUI, Verona, Italy.
This study was approved by the University of Verona Ethics Committee on 14 October 2015 (ProgCE
678CESC). All samples were collected after written informed consent was obtained from each donor.
The genetic analysis of 500 donors was performed with peripheral blood collected in Vacutainer
tubes with EDTA as an anticoagulant. Samples were centrifuged at 2,000 rpm for 10 min at room
temperature to obtain the middle ring enriched with leukocytes and platelets (buffy coat). The buffy
coats were processed to extract the genomic DNA with the EZ1 Advanced XL kit (Qiagen S.r.l., Milan,
Italy), and the extracted DNA was quantiﬁed by measuring the optical density at 260 nm (OD260) with a
spectrophotometer.
Ampliﬁcation was performed by sequence-speciﬁc oligonucleotide-primed reverse transcription-PCR
(Luminex technology) with primers speciﬁc for the second and third exons of HLA-A, -B, and -C. The
protocol was provided by Lagitre S.r.l., Milan, Italy. Data analysis was performed with the HLA Fusion
Software (One Lambda).
Donors who were selected as suitable for this study had both HLA-C alleles belonging to either the
stable group (HLA-C*02, -*05, -*06, -*08, -*12, -*15, and -*16) or the unstable group (HLA–*01, -*03, -*04,
and -*07) and who did not have HLA-B alleles cross-reactive with the L31 and DT9 MAbs used (28, 29,
31, 32). Only about 10% of the donors typed satisﬁed these requirements.
The presence/absence of an intact miRNA binding site (rs67384697 G/deletion) was conﬁrmed by a
previously described pyrosequencing approach (27, 52) that allows direct analysis of the HLA-C 3= UTR
miR-148a binding site.
PBMC puriﬁcation. Samples were obtained from donors selected according to the exclusion criteria.
PBMCs were extracted from peripheral blood collected in Vacutainer tubes with the anticoagulant EDTA
and Ficoll-Paque PLUS (GE Healthcare) in accordance with the manufacturer’s protocol. Collected cells
were aliquoted and stored in liquid nitrogen and subsequently used for ﬂow cytometry and Western blot
analyses within 2 weeks. Before use, the viability of cells consistently exceeded 90% in each sample, as
assessed by trypan blue dye exclusion. Longer storage times were avoided to ensure reproducibility of
data. When enough PBMCs were available, they were additionally used to test the ability to support HIV-1
infection.
Flow cytometry. MAb DT9, which recognizes a properly folded HLA-C/2m/peptide heterotrimer
(35), was a kind gift of A. Fenton-May and P. Borrow (Nufﬁeld Department of Clinical Medicine, University
of Oxford, Oxford, United Kingdom). MAb L31, speciﬁc for the 1 domain of HLA-C free heavy chain, not
associated with 2m (32), was provided by P. Giacomini (Regina Elena Hospital, Rome, Italy). Preliminary
experiments were conducted to compare the reactivity of PBMCs with that of lymphocytes, and no
relevant differences were observed (Fig. 1).
To achieve the highest stripping of 2m and to preserve cell viability and integrity, a classical acid
wash treatment was used to remove 2m (53, 54). This consisted of incubation of PBMCs in 0.3 M glycine
HCl and 1% bovine serum albumin in RPMI (pH 2.5) for 3 min in ice, followed by a wash in RPMI to
neutralize the pH and one in phosphate-buffered saline (PBS) prior to labeling with MAbs. PBMCs were
surface labeled with either MAb DT9 (12.5 g/ml) or L31 (1 g/ml) for 40 min at 4°C. The cells were then
washed with PBS and stained with allophycocyanin-conjugated goat anti-mouse antibody (BioLegend)
for 30 min at 4°C. Cells were washed and analyzed with a FACSCanto ﬂow cytometer. Dead cells and
debris were excluded on the basis of forward and side scatter measurements, which conﬁrmed a cell
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viability of 90% in each sample. Data were collected with the FACSDiva software (BD Biosciences),
whereas data analysis was performed with the Kaluza software (Beckman Coulter).
The results obtained from staining with both MAbs DT9 and L31 were expressed as RMFIs calculated
from median ﬂuorescence intensity (MFI) values as follows: RMFIsample (MFIsampleMFIcontrol)/MFIcontrol.
The fold change in the ﬂuorescence ratio was calculated as the ratio of RMFIs after and prior to the
acid wash for MAb L31 and between RMFIs prior to and after the acid wash for MAb DT9.
Western blotting. Protein extracts from PBMCs were spectrophotometrically quantiﬁed with Coo-
massie Plus Bradford Protein Assay Reagent (Thermo Scientiﬁc).
To evaluate the amount of HLA-C, 6 g of protein was analyzed with MAb L31 (1 g/ml). Protein
lysates from HEK-293T and Chinese hamster ovary (CHO) cells were used as an internal standard and a
negative control, respectively.
To evaluate the amount of 2m, 4 g of protein was immunoblotted with a rabbit anti-2m antibody
(12 g/ml; Abcam). HEK-293T and HEK-293T 2m-negative (20) cell lysates were used as an internal
standard and a negative control, respectively.
The /-tubulin antibody was used as a loading control in accordance with the manufacturer’s
instructions (Cell Signaling). Horseradish peroxidase-conjugated anti-mouse (Promega) or anti-rabbit
(PerkinElmer) IgG was used as a secondary antibody (0.5 g/ml). The signal was developed with the ECL
Advance Western blotting detection kit (Amersham) through the AutoChemi System UVP (BioImaging
System).
The amounts of HLA-C and 2m were quantiﬁed through densitometric analysis with ImageJ
software for OSX. Each sample value was normalized to its /-tubulin value. Differences between
experiments were normalized with the same internal standard control (HEK-293T cell lysate).
Cell lines. CHO and HEK-293T cell lines (derived from human cervical adenocarcinoma) were
obtained from the American Type Culture Collection (ATCC). 2m-negative HEK-293T cells were prepared
with the CRISPR-Cas9 system as previously reported (20). The TZM-bl cell line (39) derived from HeLa
(human cervix carcinoma) cells was provided by the EU Programme EVA Centre for AIDS Reagents,
National Institute for Biological Standards and Control (ARP5011).
These cells were cultured in Dulbecco’s modiﬁed Eagle’s medium, high glucose (Euroclone), supple-
mented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U of penicillin/ml, and 100 U of
streptomycin/ml (Lonza). The 721.221-CD4 cell line, derived from B-lymphoblastoid cells not expressing
HLA-A, -B, or -C because of the disruption of the HLA genetic locus (55), was a gift from A. Siccardi, San
Raffaele Hospital, Milan, Italy. 721.221-CD4 cells were transfected with HLA-C*06- and -*07-expressing
plasmids by nucleofection with the VCA-1003 kit (Lonza) by using the X-001 program in accordance with
Amaxa’s instructions. These cells were cultured in RPMI 1640 medium (EuroClone). The culture medium
was supplemented with 10% FBS, 2 mM L-glutamine, 100 U of penicillin/ml, and 100 U of streptomy-
cin/ml (Lonza).
All cell lines were grown at 37°C in a humidiﬁed atmosphere with 5% CO2 and routinely tested for
the absence of mycoplasma contamination.
Plasmids. HLA-C*06 and -*07 sequences were obtained by retrotranscription of mRNA from HLA-C
homozygous cell lines (MGAR and LBF, respectively) kindly provided by P. Giacomini (Regina Elena
Hospital, Rome, Italy). Both sequences were cloned into plasmid pcDNA6.2 (Invitrogen) as previously
described (20).
Infection of PBMCs and TZM-bl cells. The viability of all thawed cells, checked by trypan blue dye
exclusion, was routinely about 95 to 98%. PBMCs were activated with PHA (5 g/ml) for 48 h prior to
overnight incubation with preparations of HIV-1 BaL (R5 or CCR5 user) and IIIB (X4 or CXCR4 user) with
known titers (multiplicity of infection [MOI] range, 0.5 to 3) at 37°C. Excess virus was washed away, and
PBMCs were plated at 105/well and maintained in complete RPMI medium plus interleukin-2 (Proleukin;
Novartis) at 200 U/ml.
PBMC culture supernatants were harvested at days 8 to 12 postinfection and frozen at 20°C until
tested for p24 content. Supernatants from HIV-infected PBMCs were normalized for p24 content, and
various input concentrations were used to infect TZM-bl. Triplicate cultures were set up, and infection
was assessed after 2 days of culture.
Infection of 721.221-CD4 and TZM-bl cells. Both 721.221-CD4-C*06 and 721.221-CD4-C*07 cells
were incubated overnight with preparations of the X4-tropic HIV-1 IIB isolate with known titers (MOI
range, 0.5 to 3) at 37°C. 721.221-CD4 cell culture supernatants were harvested at day 3 postinfection and
frozen at 20°C until tested for p24 content. Four input p24 concentrations were used to infect TZM-bl
cells. Triplicate cultures were set up, and the experiment was repeated twice.
Viral replication assay. The HIV-1 structural protein p24 Gag was measured by a twin-site sandwich
enzyme-linked immunosorbent assay (ELISA; Aalto Bio Reagents Ltd., Dublin, Ireland) based on a
previously published method (56). Brieﬂy, p24 antigen was captured from a detergent lysate of virions
present in culture supernatants by a sheep polyclonal antibody adsorbed to a solid phase (3 h of
incubation at room temperature). Bound p24 was detected with a mouse alkaline phosphatase-
conjugated anti-p24 MAb (1 h of incubation) and a luminescence detection system. Luminescence was
measured with a Mithras LB 940 luminometer (Berthold Technologies, Bad Wildbad, Germany) yielding
relative luminescence units (RLU). By using a p24 internal standard curve, RLU were converted to ng/ml
values. TZM-bl cells were lysed with 0.5% NP-40 (15 min at 37°C), and then 50 l of lysate was transferred
to a 96-well ﬂat-bottom plate; this was followed by addition of the -Gal substrate chlorophenol
red--D-galactopyranoside (CPRG; Roche Applied Sciences) at 5 mg/ml. The absorbance at 570 nm was
read with an ELISA microplate reader (Bio-Rad 680), and values were expressed in OD units/min.
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Alternatively, luminescence was measured with a Victor3 luminometer (PerkinElmer) and values were
expressed in RLU.
Statistical methods. Collected data were represented by mean or median values of continuous
variables, when appropriate, and as percentages for categorical variables. Comparison of variables
between donors harboring HLA-C alleles belonging to the stable/unstable group was performed by 2
test for categorical variables and the t test or the Wilcoxon test for continuous variables. Two-way ANOVA
was used to ascertain the signiﬁcance of differences between stable and unstable HLA-C alleles in
determining viral infectivity (dependent variable) considering the experimental set as the factor of
variability. Two-way ANOVA was used to compare differences between HLA-C*06- and -*07-expressing
cells in a controlled cellular model, with the fold change in ﬂuorescence ratio as the dependent variable
and the allele (HLA-C*06/HLA-C*07) and the experiment replicas as independent variables. Two-way
ANOVA was also used to evaluate the difference in HIV-1 IIIB infectivity in 721.221-CD4 cells with virion
infectivity as the dependent variable and the allele (HLA-C*06/HLA-C*07) and the p24 concentration as
independent variables. The conventional 5% level of statistical signiﬁcance was used. Data were analyzed
with StataMP 14.0 (Stata Corp., College Station, TX, USA).
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